Logo Image

Authors

Breast Cancer Broadcast/News
Bren Simon Cancer Center
Brendan Curley, DO, MPH
Latest Article

Canine Caring: A Therapy Dog for Cancer Patients

Princess Danger was never intended to be a therapy dog. She came into our home as a pet, a goofball who immediately stole our hearts. The funny thing is that she not only stole our hearts, but that of anyone who met her.

Brian A. Moore, MD, FACS
Latest Article

Remote Monitoring Enhances Care for Patients With Head and Neck Cancer

If clinicians can identify complications earlier and take appropriate prophylactic or therapeutic measures, treatment plan adherence and outcomes may be improved for patients with head and neck cancer.

Brian A. Van Tine, MD, PhD, Siteman Cancer Center
Brian G.M. Durie, MD, Robert J. Kreitman, MD
Latest Article

ASH Interview Series

The December issue of Oncology & Biotech News featured highlights from the 51st American Society of Hematology (ASH) Annual Meeting and Exposition. We wrap up our ASH coverage this month with interviews on multiple myeloma with Brian G.M. Durie, MD, medical director and co-founder of the International Myeloma Foundation; chronic lymphocytic leukemia (CLL) with Robert J. Kreitman, MD, from the National Cancer Institute; and chronic myeloid leukemia (CML) with Francis J. Giles, MD, Cancer Therapy and Research Center at The University of Texas Health Science Center in San Antonio.

Brian J. Miles, MD
Latest Article

Focal Therapy Evolves Into More Precise Treatment in Prostate Cancer

Historically, the management of localized prostate cancer has centered on removal or ablation of the entire gland with either extirpative surgery or radiation. However, the subsequent unacceptable adverse events profile can be devastating and life altering for many patients.

Brian Larson, BS Pharm, RPh
Latest Article

Is Your Practice Ready for New Rules on Hazardous Drug Management

Among community oncology practices, the US Pharmacopeia Convention’s General Chapter draft guidelines have already raised the bar for hazardous drug management and imposed costs for compliance.

Brian M. Slomovitz, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System
Brian Olsen, MD
Latest Article

Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case Report

This is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Brian Rini,MD, Cleveland Clinic Lerner College of Medicine
Brian Rini,MD, Cleveland Clinic Main Campus
Brian Van Tine, MD, PhD, Washington University
Brice Labruzzo Mohundro, PharmD
Latest Article

On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone Therapies

A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.

Brielle Benyon
Latest Article

Rewriting the Rules for a Better Future of Cancer Care

Confidence, support, and hard work paved the way for an exceptionally successful career for Edward S. Kim, MD, MBA, who has a cemented mission in diversifying clinical trials and improving quality of life.

Brielle Urciuoli
Latest Article

Persistence and the Quest for Innovation Guided a Radiotherapy Pioneer

Herman D. Suit, MD, MSc, PhD, a leader in the field of radiation oncology whose innovations lessened the need for radical surgery and improved outcomes for patients, was honored in the Radiation Oncology category with a 2017 Giants of Cancer Care® award.

Brielle Uricioli
Brigitta Torster
Latest Article

NO-Naproxen May Protect Against Colorectal Cancer

A study presented at the AACR 101st Annual Meeting 2010 by researchers from the Fox Chase Cancer Center, Philadelphia, Pennsylvania, provides further evidence that non-steroidal anti-inflammatory drugs (NSAIDs) are promising chemopreventive agents with activity against colorectal cancer.

Britta Stordal, PhD
Latest Article

Biomarkers in Ovarian Cancer: Early Detection and Chemoresistance

Worldwide, there are ~204,000 new cases of ovarian cancer each year, accounting for 4% of cancers diagnosed in women.

Brittany Lovely, OncLive
Brittany Lovely

Managing Editor, OncLive®
Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: [email protected]


Latest Article

DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC

Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.

Broadgreen University Hospital NHS Trust
Bruce Cheson, MD, Georgetown Lombardi Comprehensive Cancer Center
Bruce Cheson, MD, Lombardi Comprehensive Cancer Center
Bruce D. Cheson, MD, FACP, FAAAS, Georgetown University Hospital
Bruce E. Johnson, MD, Dana-Farber Cancer Institute
Bryan A. Mehlhaff, MD, Oregon Urology Institute
By Alicia Bitterice, MSN, RN
Latest Article

Managing Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy is a common side effect in patients with cancer and nurses are essential to helping patients to manage this condition.

By Amy J. Hoffman, MSN, PhD, RN
Latest Article

Making the Move to Exercise

Amy Hoffman, MSN, PhD, RN, from Michigan State University's College of Nursing, offers practical tips to help initiate a regular exercise strategy for cancer patients and survivors.

By Andre Goy, MD
Latest Article

Does Lifestyle Matter to Prevent Cancer or Is It Just All “Bad Luck”?

We now have a better understanding of the sequence of events, particularly regarding the timing of these mutations, their impact, and some of the factors involved that might cause them.

By Andrew J. Bredemeyer, PhD
Latest Article

Clinical Next-Generation Sequencing to Guide Cancer Treatment Decisions

In the past year, clinical laboratories have begun determining the tumor mutational status of multiple genes simultaneously using next-generation sequencing platforms.